Cowen analyst Yaron Werber says Bluebird (NASDAQ:BLUE) reported “highly encouraging” Zynteglo data at the EHA meeting and announced higher-than-expected EU pricing.

But Bluebird also said the EMA has requested amendments, which will delay the regional launch until early 2020.

Bluebird shares are down 5.5% to $117.11.





READ SOURCE

READ  The Expert View: Barratt, Berkeley and William Hill

WHAT YOUR THOUGHTS

Please enter your comment!
Please enter your name here